Tandem Diabetes (NASDAQ: TNDM) reported Q2 EPS of $0.06, $0.14 better than the analyst estimate of ($0.08). Revenue for the quarter came in at $172.1 million versus the consensus estimate of $143.63 million.

GUIDANCE:

Tandem Diabetes sees FY2021 revenue of $670-685 million, versus the consensus of $637 million.

For earnings history and earnings-related data on Tandem Diabetes (TNDM) click here.